Elad Sharon, MD, MPH

Senior Investigator, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program
National Cancer Institute

Elad Sharon, MD, MPH, joined the NCI Cancer Therapy Evaluation Program (CTEP) in December 2011 as a Senior Investigator in the Investigational Drug Branch, where he works with academia and industry to develop promising new cancer therapies. His portfolio includes antibody-drug conjugates, immune checkpoint inhibitors and other agents. Dr. Sharon co-directs immunotherapy trials at CTEP and serves as an attending physician in NCI’s Developmental Therapeutics Clinic. As part of his work in immunotherapy drug development, he has made a major effort to advance the understanding of immune-related adverse events, including the establishment of the Alliance-NIH irAE Biorepository.  In addition, Dr. Sharon is the co-Principal Investigator of the AIM-NIVO trial, evaluating the use of nivolumab for patients with pre-existing autoimmune disease.  With the advent of Cancer Moonshot, Dr. Sharon has served as the co-chair of the Adult Immunotherapy Implementation Team to help the NCI accelerate cancer care innovation.

Dr. Sharon is on program committees for several major oncology meetings.  He has chaired the NIH-AACR Joint Conference on Cancer, Autoimmunity, and Immunology.  He has also served on the committee and chaired several ASCO pre-annual meeting seminars on the Economics of Cancer Care.  Dr. Sharon works on patterns of care projects with NCI’s Healthcare Delivery Research Program using SEER data and with NCI’s Surveillance Research Program to evaluate emerging practice patterns.  He has worked with several providers of data to evaluate real world evidence for use in drug development and patient safety analyses, through collaborations with the FDA, Friends of Cancer Research, and other stakeholders in the field.

Dr. Sharon received his M.D. from Baylor College of Medicine in Houston, Texas in 2003. He completed his internal medicine residency at Emory University in 2006 and his Hematology/Oncology Fellowship at the NIH in 2011, while obtaining a Master of Public Health degree at the Harvard University in 2009. His fellowship research focused on clinical trials in mesothelioma. During his fellowship at the NCI, he had previously worked as a guest at the Brookings Institution. He serves as an associate editor of JNCI Cancer Spectrum and on the editorial board of JCO Clinical Cancer Informatics.